Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A11 | P48066 | 4/20 | 0.37 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.37 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.37 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.37 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.37 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 6/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.33 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21873579 | 1.00 | SLC6A11 (0.37) | SLC6A11SLC6A1PLA2G2APLA2G10PLA2G1B | |
| SCHEMBL21873577 | 1.00 | SLC6A11 (0.37) | SLC6A11SLC6A1PLA2G2APLA2G10PLA2G1B | |
| SCHEMBL21873567 | 0.84 | PLA2G2A (0.33) | SLC6A11SLC6A1PLA2G2APLA2G10PLA2G1B | |
| SCHEMBL21873565 | 0.84 | PLA2G2A (0.33) | SLC6A11SLC6A1PLA2G2APLA2G10PLA2G1B | |
| SCHEMBL21873652 | 0.84 | PLA2G2A (0.33) | SLC6A11SLC6A1PLA2G2APLA2G10PLA2G1B | |
| SCHEMBL21873599 | 0.84 | KMT2A (0.39) | SLC6A11SLC6A1KIF11MEN1KMT2A | |
| SCHEMBL21873564 | 0.84 | KMT2A (0.39) | SLC6A11SLC6A1KIF11MEN1KMT2A | |
| SCHEMBL21873562 | 0.84 | KMT2A (0.39) | SLC6A11SLC6A1KIF11MEN1KMT2A | |
| SCHEMBL7869419 | 0.78 | CYP3A4 (0.33) | CYP3A4 | |
| SCHEMBL7869423 | 0.78 | CYP3A4 (0.33) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3643706-B1 | MODIFIED NUCLEIC ACID MONOMERS AND OLIGONUCLEIC ACID ANALOGUES, WITH HIGH BIOLOGICAL STABILITY AND TARGET GENE SILENCING ACTIVITY, FOR USE IN THERAPY AND DIAGNOSIS OF CANCER AND VIRAL DISEASES | EISAI R&D MAN CO LTD (JP) | 2023-11-15 | — | — | EP | disclosed |
| US-11208429-B2 | Modified nucleic acid monomer compound and oligonucleic acid analog | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-12-28 | — | — | US | disclosed |
| EP-3643706-A9 | MODIFIED NUCLEIC ACID MONOMER COMPOUND AND OLIGONUCLEIC ACID ANALOG | Eisai R&D Management Co., Ltd. (JP) | 2020-09-23 | — | — | EP | disclosed |
| US-20200216488-A1 | MODIFIED NUCLEIC ACID MONOMER COMPOUND AND OLIGONUCLEIC ACID ANALOG | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-07-09 | — | — | US | disclosed |
| EP-3643706-A1 | MODIFIED NUCLEIC ACID MONOMER COMPOUND AND OLIGONUCLEIC ACID ANALOG | Eisai R&D Management Co., Ltd. (JP) | 2020-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200216488-A1 | MODIFIED NUCLEIC ACID MONOMER COMPOUND AND OLIGONUCLEIC ACID ANALOG | POLRMT, DERA, PCNA | SLC6A11 4874/4885SLC6A1 4884/4885PLA2G2A 373/4885 |
| US-11208429-B2 | Modified nucleic acid monomer compound and oligonucleic acid analog | POLRMT, DERA, PCNA | SLC6A11 4874/4885SLC6A1 4884/4885PLA2G2A 373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.